C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of “Moderate Buy” by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.75.

Several analysts have weighed in on the stock. TD Cowen reissued a “buy” rating on shares of C4 Therapeutics in a research report on Thursday, February 26th. Wall Street Zen raised shares of C4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. upped their price objective on shares of C4 Therapeutics from $20.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a report on Monday, April 20th. Finally, Barclays upped their price objective on shares of C4 Therapeutics from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Thursday, February 26th.

Institutional Trading of C4 Therapeutics

Several large investors have recently made changes to their positions in the business. Engineers Gate Manager LP boosted its holdings in shares of C4 Therapeutics by 49.9% in the 4th quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock valued at $47,000 after acquiring an additional 8,130 shares during the last quarter. SummitTX Capital L.P. purchased a new stake in shares of C4 Therapeutics in the 1st quarter valued at $28,000. CTC Alternative Strategies Ltd. purchased a new stake in shares of C4 Therapeutics in the 1st quarter valued at $28,000. Man Group plc boosted its holdings in C4 Therapeutics by 15.0% during the third quarter. Man Group plc now owns 90,278 shares of the company’s stock worth $200,000 after buying an additional 11,791 shares in the last quarter. Finally, Zacks Investment Management purchased a new stake in C4 Therapeutics during the third quarter worth $29,000. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Trading Down 7.7%

NASDAQ:CCCC opened at $3.85 on Friday. The company has a market cap of $425.69 million, a PE ratio of -3.24 and a beta of 2.92. C4 Therapeutics has a twelve month low of $1.36 and a twelve month high of $4.60. The company’s 50 day moving average is $3.15 and its two-hundred day moving average is $2.63.

C4 Therapeutics (NASDAQ:CCCC) last released its earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.05. The company had revenue of $6.15 million for the quarter, compared to the consensus estimate of $4.42 million. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%. As a group, analysts expect that C4 Therapeutics will post -0.87 EPS for the current fiscal year.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.